KRYS · Krystal Biotech, Inc.
$332.27
+3.93 (+1.20%)
At close · Aug 14
Market Cap
$9.83B
Shares
29.60M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$332.27
Open$333.85
Day$320.62–333.85
52W close$137.46–378.15
Avg vol 30d502K
Short int3.2M · 10.8% float · 4.2d
Short vol60%
Last earningsAug 3, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 3
Up next
Next earnings call
Nov 2, 2026
Est · unconfirmed
· in 11 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 3, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Neutral
Momentum
Strong
Sentiment
Bullish
Fundamentals
Excellent
Quant / Vol
High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+19%
above
Price vs 50-day avg
−3%
below
RSI (14)
47
neutral
MACD trend
Negative
52-week position
81%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−6%
trailing
6-month return
+21%
trailing
YTD return
+35%
this year
Relative strength
+7%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $342 › 200d $279 — 50d above 200d
Institutional flow
Accumulating
+13% holders QoQ · +93 funds added
Insider flow
Distributing
Net -$8.2M over 90 days · 100% sells
Short interest
Falling
10.82% of float · ▼ -8.4% MoM · 4.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
421 holders — near 3-yr high, broad support
Squeeze score
64
elevated · 0–100
Fundamentals
Revenue growth
+34%
Y/Y
EPS growth
+128%
Y/Y
Free cash flow
$188.9M
Valuation
P/E 41.7
in line
Balance sheet
$492.1M
net cash
Quant / Vol
risk profile
Volatility
39%
annualized · 1-yr
Max drawdown
−17%
past year
ATR
4.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Feb 17, 2026
Non-GAAP Research and Development (“R&D”) and Selling, General a
· FY 2026
Non-GAAP
$175M – $195M
Prior guidance
period ended
· from the Earnings Call filed Mar 31, 2024
Combined non-GAAP, R&D, and SG&A costs
· 2024
$150M – $175M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+19%
Bullish
Price vs 50-day avg
−3%
Neutral
RSI (14)
47
Neutral
MACD trend
Negative
Bearish
52-week position
81%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $342 › 200d $279 — 50d above 200d
Institutional flow
Accumulating
+13% holders QoQ · +93 funds added
Insider flow
Distributing
Net -$8.2M over 90 days · 100% sells
Short interest
Falling
10.82% of float · ▼ -8.4% MoM · 4.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
421 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $137
Now $332 · 81%
Range high $378
vs 200-day avg +19%
vs 50-day avg -3%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Cash, cash equivalents, and investments | $1.1B | the second quarter of 2026 | — |
| Gross margin | 95% | the second quarter of 2026 | — |
| Reimbursement approvals for VYJUVEK | 730 | as of the end of 2Q 2026 | — |
| Unique prescribers | 640 | as of the end of 2Q 2026 | — |
| VYJUVEK global revenue since launch | $965.9M | since launch | — |
| VYJUVEK net product revenue | $119.2M | the second quarter of 2026 | — |
| Patients prescribed VYJUVEK therapy across Germany, France, and Japan | 90 | as of the time of the press release | — |
| Reimbursement approvals for VYJUVEK in the United States | 660 | as of the time of the press release | — |
| VYJUVEK gross margin | 94% | fourth quarter and full year of 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
KRYS
this stock
Krystal Biotech, Inc.
|
$9.83B | +34.8% | +33.9% | 41.7 | 10.8% |
|
ONC
BeOne Medicines Ltd.
|
$513.62B | +14.4% | +22179.2% | 789.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$128.19B | +11.6% | +46.2% | 29.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$82.72B | +4.1% | +20.8% | 19.9 | 3.3% |
|
ARGX
Argenx SE
|
$52.94B | +1.2% | — | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| KRYS | +1.8% | -6.4% | +21.0% | -2.6% | +34.8% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | +1.4% | -10.8% | +7.2% | -6.5% | +20.9% |
Key facts
CIK
1711279
CUSIP
501147102
13F (30d)
393 filings
392 filers
Visit website
Investor relations